| 5.62 1.35 (31.62%) | 10-06 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Applied DNA Sciences, Inc. specializes in devising and marketing sophisticated DNA-centric technological solutions across diverse sectors. Its activities encompass nucleic acid-based in vitro diagnostics and the preclinical development and production of nucleic acid-based pharmaceuticals. Furthermore, the company offers robust solutions for bolstering supply chain security, combating counterfeiting, and preventing theft. Key offerings for product authenticity and supply chain integrity include SigNature molecular tags, which imbue products with forensic traceability and protection, thereby strengthening brand defense and supply chain resilience while aiding in criminal identification and prosecution. To facilitate real-time, field-based verification of these tags, they provide SigNify IF portable DNA readers along with corresponding SigNify consumable reagent test kits. The CertainT platform represents a holistic approach, integrating tagging, testing, and tracking capabilities, empowering manufacturers, brands, and trade organizations to substantiate their product claims with verifiable evidence. Within the diagnostic realm, the company produces the LineaTM COVID-19 Assay Kit, a PCR-based molecular diagnostic test. It also offers the safeCircle COVID-19 diagnostic kit, specifically designed to help curtail viral transmission within communal settings such as schools or workplaces. Additionally, Applied DNA Sciences delivers contract research and manufacturing services for the burgeoning nucleic acid-based therapeutic markets during their preclinical phases. This extends to providing contract research for clients involved in preclinical studies of RNA-based drugs and biologics. The company is also at the forefront of developing an innovative technology for the capture and identification of invasive circulating tumor cells, utilizing a proprietary functional assay to isolate live invasive tumor cells and their associated lymphocytes. Operating internationally, the firm maintains a significant footprint across the United States, Europe, and Asia. Founded in 1983, the organization was initially known as Datalink Systems, Inc., before officially changing its name to Applied DNA Sciences, Inc. in 2002. Its corporate headquarters are located in Stony Brook, New York.
Fri, 10 Oct 2025
APDN|Applied DNA Sciences Inc|Price:5.620| - TradingKey
Tue, 07 Oct 2025
Applied DNA Sciences Restructures, Changes Ticker Symbol - The Globe and Mail
Mon, 06 Oct 2025
Applied DNA Sciences to Begin Trading Under New Ticker ‘BNBX’ Reflecting Digital Asset Treasury Strategy - Business Wire
Mon, 07 Jul 2025
Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements - USA Today
Mon, 23 Jun 2025
Dr. James A. Hayward Retires from Applied DNA Sciences - Dentistry Today
Thu, 29 May 2025
Applied DNA Announces 1-For-15 Reverse Stock Split Effective June 2, 2025 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|